Stanley Crooke - ISIS Pharmaceuticals Chairman of the Board and Presidentident, CEO
Chairman
Dr. Stanley T. Crooke M.D. Ph.D. is Chairman of the Board President Chief Executive Officer of Ionis Pharmaceuticals Inc Dr. Crooke is a founder of Ionis and was Chief Executive Officer and a Director since January 1989. He was elected Chairman of the Board in February 1991. Prior to founding Ionis from 1980 until January 1989 Dr. Crooke worked for SmithKline Beckman Corporation a pharmaceutical company where his titles included President of Research and Development of SmithKline and French Laboratories. The Board believes Dr. Crooke is uniquely suited to serve on the Board primarily because as the Chief Executive Officer and founder of Ionis he has dedicated over 26 years to discovering and developing antisense our technology platform. He is the named inventor on some of the key patents in the field of RNAtargeted therapeutics and has over 30 years of drug discovery and development experience. since 1991.
Age | 69 |
Tenure | 33 years |
Professional Marks | Ph.D |
Phone | 760-931-9200 |
Web | http://www.isispharm.com |
ISIS Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1) % which means that it has lost $0.1 on every $100 spent on assets. This is way below average. ISIS Pharmaceuticals' management efficiency ratios could be used to measure how well ISIS Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 472.07 M in liabilities with Debt to Equity (D/E) ratio of 1.92, which is about average as compared to similar companies. ISIS Pharmaceuticals has a current ratio of 6.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ISIS Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, ISIS Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ISIS Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ISIS to invest in growth at high rates of return. When we think about ISIS Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Found 14 records | CHAIRMAN Age | ||
Roderick Wendt | Jeld Wen Holding | 66 | |
Donald Washkewicz | Parker Hannifin | 64 | |
Steven Reid | Eldorado Gold Corp | 64 | |
Kirk Hachigian | Jeld Wen Holding | 58 | |
Robert Gilmore | Eldorado Gold Corp | 64 | |
Dale Corman | Western Copper And | N/A | |
Paul Barber | ServiceNow | 53 | |
Matthew Ross | Jeld Wen Holding | 43 | |
Gary Michel | Jeld Wen Holding | 58 | |
Thomas Williams | Parker Hannifin | 65 | |
MA BA | Ioneer Ltd American | 66 | |
Luvleen Sidhu | Bm Technologies | 37 | |
George Albino | Eldorado Gold Corp | 61 | |
Steve Reid | Eldorado Gold Corp | 63 |
Management Performance
Return On Asset | -0.1 |
ISIS Pharmaceuticals Leadership Team
Elected by the shareholders, the ISIS Pharmaceuticals' board of directors comprises two types of representatives: ISIS Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ISIS. The board's role is to monitor ISIS Pharmaceuticals' management team and ensure that shareholders' interests are well served. ISIS Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ISIS Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Joseph Loscalzo, Director | ||
Joseph Klein, Independent Director | ||
Joseph Wender, Independent Director | ||
Wade Walke, Executive Director - Corporate Communications | ||
Sarah Boyce, Chief Business Officer | ||
Brett Monia, Sr. VP of Drug Discovery and Corporate Devel. | ||
Frank Bennett, Senior Vice President - Antisense Research | ||
Stanley Crooke, Chairman of the Board and Presidentident, CEO | ||
Elizabeth Hougen, CFO and Sr. VP of Fin. | ||
Richard Geary, Sr. VP of Devel. | ||
Spencer Berthelsen, Independent Director | ||
Frederick Muto, Independent Director | ||
Breaux Castleman, Independent Director | ||
Patrick ONeil, Senior Vice President - Legal, General Counsel | ||
Lynne Parshall, COO, Corporate Secretary, Director |
ISIS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ISIS Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset | -0.1 | |||
Profit Margin | 4.48 % | |||
Operating Margin | (0.45) % | |||
Current Valuation | 6.57 B | |||
Shares Outstanding | 120.12 M | |||
Shares Owned By Insiders | 0.73 % | |||
Shares Owned By Institutions | 83.20 % | |||
Number Of Shares Shorted | 14.29 M | |||
Price To Earning | 453.36 X | |||
Price To Book | 28.20 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ISIS Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ISIS Pharmaceuticals' short interest history, or implied volatility extrapolated from ISIS Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in ISIS Stock
If you are still planning to invest in ISIS Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ISIS Pharmaceuticals' history and understand the potential risks before investing.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |